Entrepreneurial Growth | Oncolytic Virus
Wednesday, May 19, 2021
In 2020 there were a total of 60 phase I trials for Oncolytic Viruses. There are now dozens of companies pursuing some aspect of OV technology. This panel will address:
- How are small companies equipped to address the challenges of developing OV therapies better than large pharma or biotech?
- Will the success of COVID vaccines based on Adenovirus help the regulatory environment for small companies developing OV products in Europe and the USA?
- Is there a place for non-viral delivery and other immunotherapy companies to engage in the OV space? Would they bring any real advantages?
Q&A02:50 PM – 03:05 PM